<DOC>
	<DOCNO>NCT00003553</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , cyclophosphamide fludarabine , donor peripheral blood stem cell transplant help stop growth tumor cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain tumor cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine without mycophenolate mofetil methotrexate transplant may stop happen . PURPOSE : This phase II trial study well peripheral stem cell transplant work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplant Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor effect allogeneic peripheral blood stem cell transplantation ( PBSCT ) patient metastatic renal cell carcinoma . - Evaluate safety toxicity nonmyeloablative , low-intensity , preparative regimen follow HLA-matched allogeneic PBSCT patient . - Determine engraftment measure donor-recipient chimerism lymphoid myeloid lineages patient treated regimen . - Determine relationship donor-host chimerism incidence acute chronic graft-versus-host disease patient treat regimen . - Determine effect lymphocyte infusion donor-host chimerism patient population . - Determine response rate , disease-free survival , overall survival , mortality procedure tumor progression patient treat regimen . OUTLINE : - Nonmyeloablative preparative regimen : Patients receive 1 3 preparative regimen prior peripheral blood progenitor cell ( PBPC ) transplantation . ( Regimens 2 3 close accrual 10/1/03 . ) - Regimen 1 : Patients receive cyclophosphamide IV 1 hour day -7 -6 fludarabine IV 30 minute day -5 -1 . - Regimen 2 ( close accrual 10/1/03 ) : Patients receive cyclophosphamide IV 1 hour day -7 -6 , fludarabine IV 30 minute day -5 -1 , antithymocyte globulin day -5 -2 . - Regimen 3 ( close accrual 10/1/03 ) : Patients receive cyclophosphamide IV 1 hour day -8 -6 , fludarabine IV 30 minute day -5 -1 , antithymocyte globulin day -5 -2 . - PBPC transplantation : Patients undergo mobilize CD34+ PBPC transplantation day 0 . PBPC transplantation may repeat day 1 2 , deem necessary . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive 1 3 GVHD prophylaxis regimen . - Regimen 1 ( close accrual 10/17/00 ) : Patients receive cyclosporine IV 12 hour orally begin day -4 continue approximately 3 month . - Regimen 2 ( open accrual 10/17/00 2/11/02 ) : Patients receive cyclosporine regimen 1 . Patients also receive mycophenolate mofetil . - Regimen 3 ( open accrual 2/11/02 ) : Patients receive cyclosporine regimen 1 . Patients also receive methotrexate . - Donor lymphocyte infusion : Patients progressive disease day 15-30 , day 60 , day 100 , without GVHD , receive infusion ( ) donor lymphocyte . Further donor lymphocyte infusion day 100 may give discretion attend physician . Patients follow every 2 month 6 month , every 3 month 2 year , every 6 month 2Â½ year . PROJECTED ACCRUAL : A total 80 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic renal cell carcinoma amenable complete surgical resection progressive despite immunotherapy Bidimensionally evaluable clinically radiographically HLA 6/6 5/6 match family donor available No CNS metastases PATIENT CHARACTERISTICS : Age : 18 80 Performance status : ECOG 0 1 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Bilirubin great 4 mg/dL Transaminases great 3 time upper limit normal Renal : Creatinine great 2.5 mg/dL No malignancyassociated hypercalcemia ( &lt; 2.5 mmol/L ) Cardiovascular : Left ventricular ejection fraction great 40 % Pulmonary : DLCO great 65 % predict Other : Not pregnant HIV negative No major organ dysfunction would preclude transplantation No malignancy except basal cell squamous cell skin cancer No psychiatric disorder mental deficiency would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 1 month since prior treatment renal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>